Detalhe da pesquisa
1.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307807
2.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Br J Cancer
; 128(8): 1503-1513, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759720
3.
Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes")' by W. Tjalma.
Ann Oncol
; 35(1): 139-140, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37898238
4.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Ann Oncol
; 30(5): 672-705, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31046081
5.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Int J Gynecol Cancer
; 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31048403
6.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Ann Oncol
; 34(1): 33-47, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307055
7.
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Invest New Drugs
; 35(6): 766-772, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28317088
8.
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.
Ann Oncol
; 27(1): 16-41, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26634381
9.
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Invest New Drugs
; 34(6): 740-749, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27450049
10.
Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Br J Dermatol
; 175(5): 1030-1037, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27473757
11.
The ESMO guideline strategy: an identity statement and reflections on improvement.
Ann Oncol
; 26 Suppl 5: v1-7, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26314771
12.
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Invest New Drugs
; 33(2): 472-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25693886
13.
Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins.
Br J Surg
; 102(3): 212-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25627262
14.
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Br J Clin Pharmacol
; 80(1): 128-38, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25580946
15.
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
Br J Cancer
; 111(4): 651-9, 2014 Aug 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25025963
16.
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).
Ann Oncol
; 25(1): 9-15, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335854
17.
Editor's choice--hybrid treatment of thoracic, thoracoabdominal, and abdominal aortic aneurysms: a multicenter retrospective study.
Eur J Vasc Endovasc Surg
; 47(5): 470-8, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24656593
18.
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
Br J Cancer
; 108(5): 1021-6, 2013 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23403817
19.
Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.
Ann Oncol
; 24(1): 14-20, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23110808
20.
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
; 29(Suppl 4): iv259, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30285216